Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL12480281

NC(=O)c1cccc(OC(F)(F)F)c1F.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 8/20 0.44
CTNNB1 P35222 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.40
BRAF P15056 1/20 0.39
KCNK3 O14649 3/20 0.39
KCNK9 Q9NPC2 3/20 0.39
MPL P40238 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.37
CYP2C9 P11712 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12480740 0.94 SCN9A (0.44) SCN9ACTNNB1GAABRAFKCNK3
SCHEMBL30881819 0.94 SCN9A (0.44) SCN9ACTNNB1GAABRAFKCNK3
Hydrochloric Acid SCHEMBL12480345 0.92 SCN9A (0.44) SCN9ACTNNB1GAABRAFKCNK3
SCHEMBL16093747 0.82 RXRA (0.44) GAABRAFKCNK3KCNK9MPL
Trifluoroacetic Acid SCHEMBL12480286 0.81 MPL (0.43) SCN9AL3MBTL1GAAKCNK3KCNK9
SCHEMBL10976872 0.79 KCNK3 (0.43) SCN9AL3MBTL1GAABRAFKCNK3
Trifluoroacetic Acid SCHEMBL3596917 0.79 CES2 (0.55) L3MBTL1
SCHEMBL351860 0.79 CTNNB1 (0.55) SCN9ACTNNB1KCNK3KCNK9IRAK4
SCHEMBL29710969 0.79 CTNNB1 (0.55) SCN9ACTNNB1KCNK3KCNK9IRAK4
SCHEMBL9018684 0.78 HTR2B (0.39) SCN9AGAABRAFKCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 US disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 SCN9A 3437/4885CTNNB1 4402/4885L3MBTL1 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.